TEVA PHARMACEUTICAL INDUSTRIES LIMITED Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $19.12 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2021-02-10
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $19.12, a 40.40% decline from fiscal 2017.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $32.08, a 39.71% decline from fiscal 2016.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $53.21.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2018-12-31 | $19.12 10-K · filed 2021-02-10 |
| 2017-12-31 | $32.08 10-K · filed 2020-02-21 |
| 2016-12-31 | $53.21 10-K · filed 2019-02-19 |